On July 17, 2026, the U.S. Food and Drug Administration (FDA) staff raised questions concerning possible significant commercial conflicts of interest with some newly instated experts on the Pharmacy Compounding Advisory Committee ahead of the July 23-24 panel on peptides, The Washington Post reported.
The July meeting is to determine whether seven peptides, which are purported to treat ulcerative colitis, obesity, insomnia, and other conditions, should be eligible for bulk production by compounding pharmacies. According to officials, the panel members in question have worked for peptide-related businesses and clinics and have promoted peptides.
Related: RFK, Jr. Teases Deregulation of Injectable Peptides
The substances — which includes the likes of BPC-157 and Semax, to name a couple — have made a ripple effect on social media, with claims for longevity, recovery and cognition, despite the lack of clinical evidence supporting their safety or efficacy. According to reports, FDA scientists have already recommended against allowing their compounding due to this insufficient data.
The FDA review puts the U.S. public health sector at a crossroads, where the demand for modern science promising innovative aging, chronic pain and longevity therapies, has run into a lack of evidence and science to support it. If not careful, an unregulated marketplace can fill the gap.
As for the end result, the committee's recommendations could have far-reaching implications for compounders, clinicians and patients alike, influencing not only access to these increasingly popular peptides but also how the FDA balances consumer demand with evidence-based regulation.
The panel is scheduled to convene July 23-24.
